AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23741071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20645506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy with hem-o-lok clips (LAH)
Number of subjects: 120
Study 20645506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy with endo-loop (LAE)
Number of subjects: 120
Study 20645506 — intervention group
Group type: COMPARATOR
Intervention: Classic appendectomy (CA)
Number of subjects: 120
Study 18782697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-thoracic epidural anesthesia plus general anesthesia
Number of subjects: 16
Study 18782697 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia alone
Number of subjects: 16
Study 16640102 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (300 mg once daily) boosted by Ritonavir (100 mg) for 2 weeks, followed by ATV, RTV, and TDF-DF (300 mg) plus optimized NRTIs regimen.
Number of subjects: 53
Study 16640102 — intervention group
Group type: COMPARATOR
Intervention: Current HAART regimen (group 1)
Number of subjects: 53
Study 15022979 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 40
Study 15022979 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 40
Study 10949980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 g cefodizime
Number of subjects: 8
Study 10949980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 1 g cefodizime
Number of subjects: 8
Study 10949980 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin suction blister fluid (SBF) after cefodizime administration
Number of subjects: 8
Study 9612148 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled local delivery of tetracycline HCl
Number of subjects: 8
Study 9612148 — intervention group
Group type: COMPARATOR
Intervention: Scaling alone (Control)
Number of subjects: 8
Study 9612148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Test and Control)
Number of subjects: 8
Study 7935568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, 200 mg once a day
Number of subjects: 51
Study 7935568 — intervention group
Group type: COMPARATOR
Intervention: Oral amphotericin B, 800 mg three times a day
Number of subjects: 51
Study 3741534 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole, 500 mg i.v.
Number of subjects: 0
Study 3741534 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef (lamoxactam), 2 g i.v.
Number of subjects: 0
Study 30670009 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of prehabilitation (group 1, prehab)
Number of subjects: 714
Study 30670009 — intervention group
Group type: COMPARATOR
Intervention: No prehabilitation (group 2, no prehab)
Number of subjects: 714
Study 27993292 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol (5/5 μg)
Number of subjects: 3100
Study 27993292 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol (2.5/5 μg)
Number of subjects: 3100
Study 27993292 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 2.5 μg
Number of subjects: 3100
Study 27993292 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 3100
Study 27993292 — intervention group
Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 3100
Study 26169796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education and specific training (neck‐shoulder exercises, balance and aerobic training)
Number of subjects: 20
Study 26169796 — intervention group
Group type: COMPARATOR
Intervention: Pain education alone
Number of subjects: 20
Study 22824853 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropauses (MPs) - 20-second breaks every 20 minutes
Number of subjects: 16
Study 22824853 — intervention group
Group type: COMPARATOR
Intervention: Control situation (CTL)
Number of subjects: 16
Study 22824853 — intervention group
Group type: EXPERIMENTAL
Intervention: Without micropauses (WOMP)
Number of subjects: 16
Study 22824853 — intervention group
Group type: EXPERIMENTAL
Intervention: With micropauses (WMP)
Number of subjects: 16
Study 21109234 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 40
Study 21109234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20455795 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions for depression
Number of subjects: 0
Study 20455795 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17477110 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone in combination with 17β‐estradiol
Number of subjects: 0
Study 15110210 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographically pulsed spiral computed tomographic protocol
Number of subjects: 0
Study 15110210 — intervention group
Group type: COMPARATOR
Intervention: Sequential acquisition protocol
Number of subjects: 0
Study 11812391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (H1 and E1) - solution containing 50 g l(‐1) glucose and 1.34 g l(‐1) NaCl in a volume of water corresponding to 100% of body weight loss
Number of subjects: 7
Study 11812391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (H1 and E1)
Number of subjects: 7
Study 11812391 — intervention group
Group type: COMPARATOR
Intervention: Control condition (H0, E0) - solution containing the same quantity of glucose diluted in 100 ml of water
Number of subjects: 7
Study 11812391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration conditions (H0 and E0)
Number of subjects: 7
Study 9922072 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase condom use
Number of subjects: 246
Study 9922072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 246
Study 8044011 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang Granule (type I)
Number of subjects: 38
Study 8044011 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Tang Granule (type III)
Number of subjects: 38
Study 8044011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 3128114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm single dose)
Number of subjects: 90
Study 3128114 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 gm doses)
Number of subjects: 90
Study 8518779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation via Tracheostomy (TIPPV)
Number of subjects: 17
Study 8518779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation via Nasal Mask (NIPPV)
Number of subjects: 17
Study 319116 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (800 mg/day)
Number of subjects: 18
Study 319116 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (80 mg/day)
Number of subjects: 18
Study 319116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30735919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus metronomic chemotherapy (capecitabine 500 mg three times per day and cyclophosphamide 50 mg/die)
Number of subjects: 232
Study 30735919 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 232
Study 30735919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus metronomic chemotherapy (capecitabine and cyclophosphamide)
Number of subjects: 232
Study 30735919 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 232
Study 28198498 — intervention group
Group type: COMPARATOR
Intervention: Sugarcane genotypes (varieties RB92579 and RB867515 as controls)
Number of subjects: 12
Study 26012839 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple line graphs for group-level data
Number of subjects: 70
Study 26012839 — intervention group
Group type: COMPARATOR
Intervention: Line graphs with confidence limits or norms for group-level data
Number of subjects: 70
Study 26012839 — intervention group
Group type: EXPERIMENTAL
Intervention: Line graphs for individual-level data
Number of subjects: 70
Study 22404081 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment using removable partial dentures
Number of subjects: 44
Study 22404081 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment using resin-bonded bridgework (RBB) to restore to a Shortened Dental Arch (SDA) of 10 occluding contacts
Number of subjects: 44
Study 22001281 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV//PRP∼T (Pentaxim®) booster
Number of subjects: 719
Study 22001281 — intervention group
Group type: COMPARATOR
Intervention: Separate vaccines (DTaP, IPV, PRP∼T) booster
Number of subjects: 719
Study 19858155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (maximum dose: 30 microg per meal)
Number of subjects: 10
Study 16622259 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 43 mg/m2 weekly alone (cohort A)
Number of subjects: 12
Study 16622259 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 43 mg/m2 weekly plus etanercept 25 mg subcutaneously twice weekly (cohort B)
Number of subjects: 12
Study 16622259 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 52 mg/m2 weekly with etanercept
Number of subjects: 12
Study 16622259 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept/docetaxel
Number of subjects: 12
Study 15642958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin formulations (Cotecxin, Arenco n.v. Pharmaceutica, Mahidol University)
Number of subjects: 0
Study 15642958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin formulations
Number of subjects: 0
Study 15642958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo model
Number of subjects: 0
Study 11590630 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoint analysis using a joint model for the surrogate and the true endpoint
Number of subjects: 0
Study 11590630 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary surrogate endpoint
Number of subjects: 0
Study 11590630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal endpoints
Number of subjects: 0
Study 11590630 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analytic context
Number of subjects: 0
Study 9849452 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus chemotherapy (carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses)
Number of subjects: 48
Study 9849452 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 48
Study 7812703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (exact regimen not specified)
Number of subjects: 2196
Study 7812703 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised model for identifying high-risk patients (including factors such as WHO PS ≥2 and white blood cell count > 10,000/mm3)
Number of subjects: 2196
Study 7812703 — intervention group
Group type: COMPARATOR
Intervention: Half doses of drugs at the first cycle (suggested intervention)
Number of subjects: 2196
Study 2691252 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 97
Study 2691252 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 97
Study 31729127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide
Number of subjects: 11140
Study 31729127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea gliclazide plus other glucose-lowering drugs targeting a glycated hemoglobin value of 6.5% or less
Number of subjects: 11140
Study 31729127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 31729127 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 30663196 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 279
Study 28691761 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples communication skills training (CCST)
Number of subjects: 32
Study 28691761 — intervention group
Group type: COMPARATOR
Intervention: Education comparison intervention
Number of subjects: 32
Study 25675123 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (once daily)
Number of subjects: 86
Study 25675123 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (3-weekly cycles)
Number of subjects: 86
Study 23241734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 90
Study 23241734 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 90
Study 23241734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam-Paracetamol combination
Number of subjects: 90
Study 23241734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and Paracetamol combination
Number of subjects: 90
Study 21533969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh fixation
Number of subjects: 104
Study 21533969 — intervention group
Group type: COMPARATOR
Intervention: Mesh nonfixation
Number of subjects: 104
Study 19040340 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs and new approaches including response prediction based on sequential (18)FDG‐PET scanning following induction chemotherapy
Number of subjects: 0
Study 16949590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 310
Study 16949590 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 310
Study 12930166 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate (CM)
Number of subjects: 29
Study 12930166 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate and Glutamine (CG)
Number of subjects: 29
Study 12930166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 29
Study 11765879 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Development Review (CDR)
Number of subjects: 73
Study 11765879 — intervention group
Group type: COMPARATOR
Intervention: Denver II Developmental Screening Test (Denver II)
Number of subjects: 73
Study 9973775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pommel Horse (PH)
Number of subjects: 5
Study 9973775 — intervention group
Group type: EXPERIMENTAL
Intervention: Roman Ring (RR)
Number of subjects: 5
Study 9973775 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel Bar (PB)
Number of subjects: 5
Study 9973775 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Bar (HB)
Number of subjects: 5
Study 9973775 — intervention group
Group type: EXPERIMENTAL
Intervention: Floor Exercise (FE)
Number of subjects: 5
Study 8057515 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized glycemic control (subcutaneous insulin given several times a day or continuously)
Number of subjects: 48
Study 8057515 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control (subcutaneous insulin given once or twice each day)
Number of subjects: 48
Study 8057515 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 48
Study 8057515 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized treatment
Number of subjects: 48
Study 8057515 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized glycemic control
Number of subjects: 48
Study 3140744 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (25 g/day, n = 16)
Number of subjects: 30
Study 3140744 — intervention group
Group type: COMPARATOR
Intervention: L-glycine (43 g/day, n = 14)
Number of subjects: 30
Study 31513665 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 inhibitor)
Number of subjects: 39
Study 31513665 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab, golimumab)
Number of subjects: 39
Study 31513665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Anakinra and TNFi)
Number of subjects: 39
Study 29021371 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS) containing 47 mg potassium iodate/kg and 3.3 mg microencapsulated ferrous fumarate/g (1.1 mg elemental Fe/g)
Number of subjects: 126
Study 29021371 — intervention group
Group type: COMPARATOR
Intervention: Control iodized salt
Number of subjects: 126
Study 26643548 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional brain β-amyloid (Aβ) measured with [18F]florbetapir PET
Number of subjects: 128
Study 26643548 — intervention group
Group type: COMPARATOR
Intervention: Demographic variables, BMI, and APOE status
Number of subjects: 128
Study 24631312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 538
Study 22912456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary choline supplementation at 2,960 mg/kg
Number of subjects: 240
Study 22912456 — intervention group
Group type: COMPARATOR
Intervention: Dietary choline supplementation at 370 mg/kg
Number of subjects: 240
Study 19330795 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine SR (75-150 mg/die)
Number of subjects: 50
Study 19330795 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/die)
Number of subjects: 50
Study 17848609 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml wine (13 g alcohol) daily for 3 months
Number of subjects: 109
Study 17848609 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic diet beer (control) daily for 3 months
Number of subjects: 109
Study 15171814 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of specific serum autoantibodies associated with neurological paraneoplastic syndromes
Number of subjects: 0
Study 15171814 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterization of anti-neuronal autoantibodies
Number of subjects: 0
Study 15171814 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltage-gated ion channels as targets for autoantibodies
Number of subjects: 0
Study 11780926 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg BMS-193884
Number of subjects: 53
Study 11780926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15512224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin combined with fish oil
Number of subjects: 60
Study 15512224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin only
Number of subjects: 60
Study 15512224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin combined with evening primrose oil
Number of subjects: 60
Study 15512224 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil alone
Number of subjects: 60
Study 15512224 — intervention group
Group type: COMPARATOR
Intervention: Fish oil alone
Number of subjects: 60
Study 15512224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 7884952 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg TNF‐alpha MAb
Number of subjects: 994
Study 7884952 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg TNF‐alpha MAb
Number of subjects: 994
Study 7884952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 2229305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) 120 mg oral
Number of subjects: 30
Study 2229305 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms iv)
Number of subjects: 30
Study 2229305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) plus GHRH
Number of subjects: 30
Study 2229305 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH alone in diabetic patients
Number of subjects: 30
Study 2229305 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 30
Study 651762 — intervention group
Group type: EXPERIMENTAL
Intervention: Reptilase (1 ml)
Number of subjects: 0
Study 651762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31862699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg)
Number of subjects: 92
Study 31862699 — intervention group
Group type: EXPERIMENTAL
Intervention: E14 (delaying ethinylestradiol induction of puberty by 2 years)
Number of subjects: 92
Study 31150800 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.75% ropivacaine
Number of subjects: 45
Study 31150800 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of 0.75% ropivacaine
Number of subjects: 45
Study 31150800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.75% ropivacaine
Number of subjects: 45
Study 31150800 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml and 15 ml of 0.75% ropivacaine
Number of subjects: 45
Study 31150800 — intervention group
Group type: EXPERIMENTAL
Intervention: R20, R15, and R10 groups
Number of subjects: 45
Study 28321637 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric-only resistance training (dumbbell curls and shoulder presses, twice per week for 4 weeks)
Number of subjects: 13
Study 28321637 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 13
Study 25905863 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and iron supplementation
Number of subjects: 802
Study 25905863 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, iron, and multivitamin supplementation
Number of subjects: 802
Study 25905863 — intervention group
Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 802
Study 23404919 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial psychosocial functioning (parent-reported PedsQL School Functioning)
Number of subjects: 258
Study 23404919 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in psychosocial functioning (PedsQL Social and Global Self-esteem)
Number of subjects: 258
Study 23404919 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in Physical Appearance Self-esteem
Number of subjects: 258
Study 23404919 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in Desire to be Thinner
Number of subjects: 258
Study 20693490 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (SES) groups (measured by income)
Number of subjects: 1223
Study 20693490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective SES measures
Number of subjects: 1223
Study 20693490 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective SES measures
Number of subjects: 1223